Type:Capsule
Generic Name:Zonisamide
Manufacturer:Beacon Pharmaceuticals Ltd.
Price:৳15.00
Adjunct in partial seizures, Monotherapy for partial seizures with or without secondary generalisation
May be taken with or without food.
Oral Adjunct in partial seizures Adult: Initially, 50 mg daily in 2 divided doses, increase to 100 mg daily after 1 wk. Thereafter, may further increase dose at wkly intervals in increments of up to 100 mg. Usual maintenance dose: 300-500 mg daily, some patients may respond to lower doses. Monotherapy for partial seizures with or without secondary generalisation Adult: In patients w/ newly diagnosed epilepsy: Initially, 100 mg once daily, increase to 200 mg once daily after 2 wk. May further increase by increments of 100 mg at intervals of at least 2 wk. Usual maintenance dose: 300 mg once daily, up to 500 mg daily. Hepatic impairment: Mild to moderate: Slower dosage titration may be needed. Severe: Not recommended.
Oral Adjunct in partial seizures Child: >6 yr Initially, 1 mg/kg once daily for 1 wk, may increase by increments of 1 mg/kg at wkly interval. Usual maintenance dose: 20-55 kg: 6-8 mg/kg once daily; >55 kg: 300-500 mg once daily, some may respond to lower dose.
Renal impairment: GFR ?50 mL/min: Slower dosage titration may be needed. GFR <50 mL/min: Not recommended.
Hypersensitivity to zonisamide or sulfonamides
Zonisamide is a benzisoxazole derivative anticonvulsant containing sulfonamide. It may act on voltage sensitive Na and Ca channels, thereby affecting neuronal firing, hence reducing the spread of seizure discharges. It may modulate GABA-mediated neuronal inhibition.
Patient at risk of nephrolithiasis. Avoid abrupt withdrawal. Renal or hepatic impairment. Childn. Pregnancy and lactation. Patient Counselling Increase fluid intake (i.e. 6-8 glasses of water/day) to reduce risk of renal stone. This drug may cause drowsiness or difficulty w/ concentration, if affected, do not drive or operate machinery. Increase in suicidal ideation may occur with use. Monitoring Parameters Monitor metabolic profile specifically BUN, serum creatinine; serum bicarbonate, body temp, suicidality, decreased sweating. Lactation: Unknown; avoid during breastfeeding
>10% Somnolence (17%) Anorexia (13%) Dizziness (13%) 1-10% Headache (10%) Nausea (9%) Agitation (9%) Abdominal pain (6%) Ataxia (6%) Confusion (6%) Depression (6%) Diplopia (6%) Insomnia (6%) Diarrhea (5%) Speech disorder (5%) Flu-like symptoms (4%) Kidney stones (4%) Nystagmus (4%) Paresthesia (4%) Dysgeusia (3%) Weight loss (3%) Anxiety (3%) Rash (3%) Constipation (2%) Rhinitis (2%) Xerostomia (2%)
Reduced plasma concentration w/ phenytoin, phenobarbital, carbamazepine. Increased risk of metabolic acidosis w/ carbonic anhydrase inhibitors (e.g. acetazolamide).